Editorial: Hypertonic glucose and improved critical organ performance.
D000249:Adenosine Monophosphate / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000378:metabolism; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D002056:Burns / Q000188:drug therapy; D005947:Glucose / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006982:Hypertonic Solutions; D007003:Hypoglycemia / Q000209:etiology; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010477:Perfusion; D011188:Potassium / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012771:Shock, Hemorrhagic / Q000188:drug therapy / Q000378:metabolism
D000317:Adrenergic alpha-Antagonists; D006982:Hypertonic Solutions; D007328:Insulin; D000249:Adenosine Monophosphate; D000255:Adenosine Triphosphate; D005947:Glucose; D011188:Potassium